NCT06126588View on ClinicalTrials.gov

Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 29, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

May 1, 2028

Conditions
Meningioma
Interventions
DRUG

Everolimus

Patient will be treat during 7 months of Everolimus

Trial Locations (2)

54511

NOT_YET_RECRUITING

CHRU of Nancy, Vandœuvre-lès-Nancy

RECRUITING

Nancy Hospital, Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER